Group treatment for smoking cessation among persons with schizophrenia
Group treatment for smoking cessation among persons with schizophrenia
复制标题
DOI：
10.1176/ps.49.7.925
复制
发表时间：
1998-07-01
影响因子：
3.8
通讯作者：
Addington, J
中科院分区：
文献类型：
--
作者：
Addington, J
精神分裂症患者比一般人群吸烟更多，也比其他精神病诊断组吸烟更多。一般人群的吸烟率为30%，精神分裂症患者的吸烟率在62%到81%之间。作者简要回顾了尼古丁增加多巴胺释放的证据，这可能是这一群体吸烟率高的原因。许多精神分裂症患者所经历的情感、认知和社交困难以及症状表明，现有的戒烟计划可能不适合他们。作者介绍了三个程序开发用于这一人群，并审查其有效性的证据。初步证据表明，尼古丁透皮贴剂是有效的，患者不会滥用它们。作者的结论是，对于精神分裂症患者来说，戒烟是可能的，特别是如果治疗是专门为他们设计的。
People with schizophrenia smoke more than the general population and more than other psychiatric diagnostic groups. The rate of smoking in the general population is 30 percent, and reported rates for people with schizophrenia range between 62 percent and 81 percent. The author briefly reviews evidence that nicotine's augmentation of dopamine release may account for the high prevalence of smoking in this group. The affective, cognitive, and social difficulties and the symptoms experienced by many patients with schizophrenia indicate that existing smoking cessation programs may not be appropriate for them. The author describes three programs developed for use with this population and reviews evidence of their effectiveness. Preliminary evidence suggests that transdermal nicotine patches are effective and that patients do not misuse them. The author concludes that stopping smoking is possible for individuals with schizophrenia, especially if the treatment is specifically designed for them.